From: Tumor immunogenomic signatures improve a prognostic model of melanoma survival
Model (adjusted by age and stage at primary diagnosis) | Discovery (N = 139) P | Validation 2 (N = 69) P | Pooled (Discovery + Validation 2, N = 208) P | Meta (N = 278) P |
---|---|---|---|---|
TMB + MacReg + IFNγRes | 1.70E−07 | 1.28E−02 | 3.37E−10 | 8.80E−14 |
TMB + IFNγRes | 1.71E−07 | 1.74E−02 | 8.26E−10 | 2.09E−13 |
MacReg * IFNγRes + TMB | 2.16E−07 | 1.03E−02 | 1.12E−09 | 3.30E−13 |
TMB + Lymphocyte infiltration signature score + IFNγRes | 2.84E−07 | 1.44E−02 | 6.87E−10 | 2.88E−13 |
TMB + MacReg | 2.90E−07 | 6.66E−03 | 5.23E−10 | 2.64E−13 |
Lymphocyte infiltration signature score * IFNγRes + TMB | 3.24E−07 | 2.51E−02 | 1.97E−09 | 1.10E−12 |
TMB * MacReg + IFNγRes | 3.40E−07 | 2.26E−03 | 6.04E−10 | 9.59E−14 |
TMB * IFNγRes + MacReg | 3.53E−07 | 2.22E−02 | 1.18E−09 | 3.46E−13 |
Lymphocyte infiltration signature score * IFNγRes + TMB + MacReg | 4.07E−07 | 3.80E−02 | 3.05E−09 | 1.02E−12 |
TMB * IFNγRes | 4.84E−07 | 3.16E−02 | 3.04E−09 | 9.12E−13 |